7 Interactions found for:
Drug Interactions
Moderate
Metoprolol
+ Jardiance
The following applies to the ingredients: Metoprolol and Empagliflozin (found in Jardiance)
Using empagliflozin together with metoprolol may increase the risk of low blood pressure. You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate. Use caution when getting up from a sitting or lying position, and let your doctor know if you develop these symptoms. Keep yourself hydrated by drinking plenty of fluids unless otherwise directed. You should seek medical advice immediately if you have reduced oral intake (for example, due to acute illness) or increased fluid loss (for example, due to vomiting, diarrhea, or excessive heat exposure), as it may be appropriate to interrupt one or both medications temporarily under these circumstances. In addition, metoprolol may interfere with blood glucose control thus increasing or reducing the effectiveness of empagliflozin and other diabetic medications. Metoprolol may also mask some of the symptoms of hypoglycemia such as tremor, palpitations and rapid heartbeat, making it more difficult to recognize an oncoming episode. However, other symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, nausea, hunger, weakness, and perspiration are not affected. Monitor your blood glucose levels more frequently, particularly if you are prone to developing hypoglycemia. You may need a dose adjustment of your diabetic medications during and after treatment with metoprolol. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and Food Interactions
Moderate
Metoprolol
+ Food
The following applies to the ingredients: Metoprolol
Food can enhance the levels of metoprolol in your body. You should take metoprolol at the same time each day, preferably with or immediately following meals. This will make it easier for your body to absorb the medication. Avoid drinking alcohol, which could increase drowsiness and dizziness while you are taking metoprolol. Metoprolol is only part of a complete program of treatment that also includes diet, exercise, and weight control. Follow your diet, medication, and exercise routines very closely.
The following applies to the ingredients: Metoprolol
Using metoprolol together with multivitamin with minerals may decrease the effects of metoprolol. Separate the administration times of metoprolol and multivitamin with minerals by at least 2 hours. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Moderate
Jardiance
+ Food
The following applies to the ingredients: Empagliflozin (found in Jardiance)
Alcohol may affect blood glucose levels in patients with diabetes. Both hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) may occur, depending on how much and how often you drink. You should avoid using alcohol if your diabetes is not well controlled or if you have high triglycerides, neuropathy (nerve damage), or pancreatitis. Moderate alcohol consumption generally does not affect blood glucose levels if your diabetes is under control. However, it may be best to limit alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with your normal meal plan. Avoid drinking alcohol on an empty stomach or following exercise, as it may increase the risk of hypoglycemia. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and Pregnancy Interactions
Major
Metoprolol
+ Pregnancy
The following applies to the ingredients: Metoprolol
Professional Content
Safety has not been established during pregnancy.
-According to some authorities: Use is not recommended unless benefit outweighs risk; if used during pregnancy, administer the lowest possible dose and discontinue at least 2 to 3 days prior to expected delivery, if possible.
AU TGA pregnancy category: C
US FDA pregnancy category: Not assigned
Risk summary: Inconclusive data available on the use of this drug in pregnant women to inform a drug-related risk.
Comments:
-Based on published literature, this drug may cause erectile dysfunction and inhibit sperm motility.
Animal studies have revealed increased post-implantation loss, fetolethality, and decreased neonatal survival. This drug crosses placenta, neonates born to mothers who are receiving metoprolol during pregnancy, may be at risk for hypotension, hypoglycemia, bradycardia, and respiratory depression.
AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
References
- "Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals PROD (2001):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Kapspargo Sprinkle (metoprolol)." Sun Pharmaceutical Industries (2023):
- "Product Information. Toprol-XL (metoprolol)." Melinta Therapeutics, Inc. (2023):
- "Product Information. Lopressor (metoprolol)." Validus Pharmaceuticals LLC (2025):
- "Product Information. Metoprolol Tartrate (obsolete) (metoprolol)." Hikma USA (formerly West-Ward Pharmaceutical Corporation) (2025):
Major
Jardiance
+ Pregnancy
The following applies to the ingredients: Empagliflozin (found in Jardiance)
Professional Content
Use should be avoided, especially during the second and third trimesters of pregnancy.
AU TGA pregnancy category: D
US FDA pregnancy category: Not Assigned
Risk Summary: There is limited data in pregnant women to determine a drug-associated risk for major birth defects and miscarriage. Based on animal data, this drug may cause adverse renal effects in the developing fetus.
Comments:
-Poorly controlled diabetes in pregnancy increases the risk of adverse maternal and fetal outcomes.
Animal studies have revealed evidence of adverse renal changes and embryofetal toxicity. Administration of this drug to pregnant animals during the period of organogenesis at doses up to 154 times the maximum clinical dose based on AUC resulted in maternal/fetal toxicity, malformations, and reduced offspring body weights. In juvenile rats, direct exposure to this drug at doses approximately 13 times the maximum clinical dose caused increased kidney weights and renal tubular/pelvic dilatations. These findings occurred during a period of renal development in rats corresponding to the late second and third trimester of human renal development. Animal studies do not indicate direct or indirect harmful effects with respect to fertility. There are no controlled data in human pregnancy.
Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth, and delivery complications. Fetal risks of poorly controlled diabetes in pregnancy include an increased risk for major birth defects, stillbirth, and macrosomia-related morbidity.
AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
References
- "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim Ltd (2023):
- "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim SUPPL-42 (2023):
- "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim Pty Ltd (2024):
Drug and Breastfeeding Interactions
Major
Metoprolol
+ Breastfeeding
The following applies to the ingredients: Metoprolol
Professional Content
AU and UK: Use is not recommended unless benefit outweighs risk.
US: This drug has been used without apparent harmful effects; caution is recommended.
Excreted into human milk: Yes (in small amounts)
Comments: This drug has been used without apparent harmful effects in the nursing infant.
An infant consuming 1 L of breast milk a day would receive a dose of less than 1 mg of drug.
References
- "Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals PROD (2001):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
Major
Jardiance
+ Breastfeeding
The following applies to the ingredients: Empagliflozin (found in Jardiance)
Professional Content
Use is not recommended
Excreted into human milk: Unknown
Excreted into animal milk: Yes
Comments:
-A risk to the breastfed infant cannot be excluded; there is a potential for serious adverse effects on postnatal renal development.
-An alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug accumulation was observed in the milk of lactating animals. Studies in juvenile rats with direct exposure demonstrated pelvic and tubular dilations of the kidney during maturation. Human kidney maturation occurs in utero and during the first 2 years of life; thus, a potential for serious harm to the developing kidney may exist for infants exposed to this drug during breastfeeding. However, some experts anticipate low amounts of this drug in human breastmilk due to high levels of plasma protein binding.
References
- "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim Ltd (2023):
- "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim SUPPL-42 (2023):
- Bethesda (MD): National Institute of Child Health and Human Development (US) "Empagliflozin - Drugs and Lactation Database (LactMed) https://www.ncbi.nlm.nih.gov/books/NBK500972/" (2023):
- "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim Pty Ltd (2024):
Therapeutic Duplication Warnings
No warnings were found for your selected drugs.Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Switch to: Professional Interactions
| Drug Interaction Classification | |
|---|---|
These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication. |
|
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
| Unknown | No interaction information available. |
Disclaimer: This content should not be considered complete and should not be used in place of a call or visit to a healthcare professional. Use of this content is subject to our terms of use & medical disclaimer.